Ken O’Day

461 total citations
40 papers, 333 citations indexed

About

Ken O’Day is a scholar working on Economics and Econometrics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ken O’Day has authored 40 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Economics and Econometrics, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in Ken O’Day's work include Health Systems, Economic Evaluations, Quality of Life (9 papers), Cardiac Imaging and Diagnostics (6 papers) and Pharmaceutical Economics and Policy (5 papers). Ken O’Day is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (9 papers), Cardiac Imaging and Diagnostics (6 papers) and Pharmaceutical Economics and Policy (5 papers). Ken O’Day collaborates with scholars based in United States, United Kingdom and France. Ken O’Day's co-authors include Kellie Meyer, James K. Min, Amanda Gilmore, Daniel S. Berman, Matthew J. Budoff, Krithika Rajagopalan, Sonalee Agarwal, Ross M. Miller, A. Loebel and Daniel A. Barocas and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Ken O’Day

36 papers receiving 330 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ken O’Day United States 11 119 57 55 53 50 40 333
Timothy Baker United States 10 56 0.5× 70 1.2× 64 1.2× 54 1.0× 127 2.5× 27 445
Eric J. Lee United States 11 69 0.6× 48 0.8× 36 0.7× 10 0.2× 30 0.6× 18 315
Stefania Lopatriello Italy 10 52 0.4× 29 0.5× 46 0.8× 68 1.3× 39 0.8× 35 340
Clemens Lang Austria 10 109 0.9× 136 2.4× 29 0.5× 10 0.2× 52 1.0× 32 311
Danny Chan United Kingdom 6 54 0.5× 62 1.1× 86 1.6× 11 0.2× 195 3.9× 8 424
Haichen Lv China 12 60 0.5× 32 0.6× 116 2.1× 13 0.2× 172 3.4× 36 376
George Tran United States 10 51 0.4× 31 0.5× 28 0.5× 152 2.9× 138 2.8× 19 482
Christian Lopez Ramos United States 9 31 0.3× 35 0.6× 61 1.1× 11 0.2× 23 0.5× 19 289
Majd El‐Harasis United States 11 28 0.2× 69 1.2× 170 3.1× 27 0.5× 183 3.7× 23 454
Paul Y. Song United States 7 119 1.0× 223 3.9× 60 1.1× 9 0.2× 46 0.9× 26 705

Countries citing papers authored by Ken O’Day

Since Specialization
Citations

This map shows the geographic impact of Ken O’Day's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken O’Day with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken O’Day more than expected).

Fields of papers citing papers by Ken O’Day

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken O’Day. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken O’Day. The network helps show where Ken O’Day may publish in the future.

Co-authorship network of co-authors of Ken O’Day

This figure shows the co-authorship network connecting the top 25 collaborators of Ken O’Day. A scholar is included among the top collaborators of Ken O’Day based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken O’Day. Ken O’Day is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Meyer, Kellie, et al.. (2023). Practice efficiency of treatment with epcoritamab versus glofitamab in relapsed/refractory diffuse large B-cell lymphoma.. Journal of Clinical Oncology. 41(16_suppl). e18919–e18919. 1 indexed citations
4.
Suthoff, Ellison, Brian Werneburg, Paul Hodgkins, et al.. (2021). Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder. Journal of Affective Disorders. 285. 112–119. 16 indexed citations
5.
Min, James K., Amanda Gilmore, Erica C. Jones, et al.. (2017). Cost-effectiveness of diagnostic evaluation strategies for individuals with stable chest pain syndrome and suspected coronary artery disease. Clinical Imaging. 43. 97–105. 19 indexed citations
6.
O’Day, Ken, et al.. (2016). What’s The Matter With Average Cost-Effectiveness Ratios? A Simple Graphical Explanation. Value in Health. 19(3). A107–A108. 1 indexed citations
7.
8.
9.
Min, James K., et al.. (2015). Costs and clinical outcomes for non-invasive versus invasive diagnostic approaches to patients with suspected in-stent restenosis. International journal of cardiac imaging. 32(2). 309–315. 4 indexed citations
10.
11.
Rajagopalan, Krithika, et al.. (2015). Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression. Journal of Medical Economics. 18(10). 821–827. 5 indexed citations
12.
O’Day, Ken, Cat N. Bui, Scott C. Flanders, et al.. (2015). MP73-13 BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FROM A US PAYER PERSPECTIVE. The Journal of Urology. 193(4S). 1 indexed citations
13.
14.
15.
O’Day, Ken, et al.. (2013). Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. ClinicoEconomics and Outcomes Research. 5. 459–459. 18 indexed citations
16.
Eaddy, Michael, et al.. (2012). Economic Implications of Rasburicase Treatment in Adult Patients with Tumour Lysis Syndrome. Applied Health Economics and Health Policy. 10(6). 431–440. 4 indexed citations
17.
O’Day, Ken, et al.. (2011). Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. Journal of Medical Economics. 14(5). 617–627. 36 indexed citations
18.
19.
Gilmore, Amanda, Fay Y. Lin, Daniel S. Berman, et al.. (2010). COST-EFFECTIVENESS OF ALTERNATIVE DIAGNOSTIC EVALUATION PATHWAYS FOR INDIVIDUALS WITH STABLE CHEST PAIN SYNDROME WITHOUT KNOWN CORONARY ARTERY DISEASE. Journal of the American College of Cardiology. 55(10). A75.E705–A75.E705. 1 indexed citations
20.
Null, Donald M., et al.. (2008). THE ECONOMIC BURDEN OF BRONCHOPULMONARY DYSPLASIA DURING THE FIRST TWO YEARS OF LIFE. Archives of Disease in Childhood. 93. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy Baker Breakdown of academic impact, for papers by Eric J. Lee Breakdown of academic impact, for papers by Stefania Lopatriello Breakdown of academic impact, for papers by Clemens Lang Breakdown of academic impact, for papers by Danny Chan Breakdown of academic impact, for papers by Haichen Lv Breakdown of academic impact, for papers by George Tran Breakdown of academic impact, for papers by Christian Lopez Ramos Breakdown of academic impact, for papers by Majd El‐Harasis Breakdown of academic impact, for papers by Paul Y. Song
Rankless by CCL
2026